Potassium-Competitive Acid Blockers and Esophagoprotective Agents in the Management of Gastroesophageal Reflux Disease
DOI:
https://doi.org/10.67076/cmj.2026.v4n2.01Keywords:
gastroesophageal reflux disease, P-CABs, vonoprazan, erosive esophagitis, esophagoprotection, hyaluronic acid, chondroitin sulfate, refractory GERDAbstract
Gastroesophageal reflux disease (GERD) is a heterogeneous disorder arising from multiple pathophysiological mechanisms, including impairment of the antireflux barrier, transient lower esophageal sphincter relaxations, hiatal hernia, abnormal esophageal acid exposure, defective esophageal clearance, epithelial barrier dysfunction, and visceral hypersensitivity. Consequently, acid suppression alone does not provide adequate symptom control in all patients.
Current consensus consider P-CAB drugs, along with proton pump inhibitors, as an option for initial and maintenance therapy for certain disease phenotypes. An additional approach is esophageal protection: the use of drugs that reduce the contact of refluxate with the mucosa and support the restoration of the epithelial barrier. These include alginates, sucralfate and mucoadhesive complexes of hyaluronic acid and chondroitin sulfate. The most justified indications for their use are postprandial heartburn, regurgitation and residual symptoms despite adequate acid suppression. However, the level of evidence for esophageal protectors remains lower than for proton pump inhibitors and P-CABs.
The article discusses modern principles of phenotype-oriented drug therapy for gastroesophageal reflux disease, the specifics of using P-CABs and esophagoprotectors as well as an algorithm for managing patients with a suspected refractory form of the disease.
References
Hunt R., Armstrong D., Katelaris P. et al. WGO Global Guidelines GERD. © World Gastroenterology Organization 2015.
Aghayeva S., Katzka D., Afandiyeva N., Bor S., et al. The Prevalence of Gastroesophageal Reflux Disease in Azerbaijan: A Population-Based Cross-sectional Study. Turk J Gastroenterol. 2023 Nov 1;34(11):1134–1142. doi: 10.5152/tjg.2023.211042 DOI: https://doi.org/10.5152/tjg.2023.211042
Gyawali CP, Yadlapati R, Fass R, Katzka D, Pandolfino JE, Savarino E, et al. Updates to the modern diagnosis of GERD: Lyon Consensus 2.0. Gut. 2024;73(2):361–371. doi:10.1136/gutjnl-2023-330616. DOI: https://doi.org/10.1136/gutjnl-2023-330616
Desai M, Ruan W, Thosani NC, Amaris M, Scott JS, Saeed A, et al; ASGE Standards of Practice Committee. American Society for Gastrointestinal Endoscopy guideline on the diagnosis and management of GERD: summary and recommendations. Gastrointest Endosc. 2025;101(2):267–284. doi:10.1016/j.gie.2024.10.008. DOI: https://doi.org/10.1016/j.gie.2024.10.008
Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117(1):27–56. doi:10.14309/ajg.0000000000001538. DOI: https://doi.org/10.14309/ajg.0000000000001538
Patel A, Yadlapati R, Vaezi MF. AGA Clinical Practice Update on integrating potassium-competitive acid blockers into clinical practice: expert review. Gastroenterology. 2024;167. doi:10.1053/j.gastro.2024.06.038. DOI: https://doi.org/10.1053/j.gastro.2024.06.038
Laine L, DeVault K, Katz P, Mitev S, Lowe J, Hunt B, Spechler S. Vonoprazan versus lansoprazole for healing and maintenance of healing of erosive esophagitis: a randomized trial. Gastroenterology. 2023;164(1):61–71. doi:10.1053/j.gastro.2022.09.041. DOI: https://doi.org/10.1053/j.gastro.2022.09.041
Huh CW, et al. 2025 focused update of the Seoul Consensus on gastroesophageal reflux disease. J Neurogastroenterol Motil. Published online 2025. doi:10.5056/jnm25128. DOI: https://doi.org/10.5056/jnm25128
Laine L, Spechler S, Yadlapati R, Schnoll-Sussman F, Smith N, Leifke E, et al. Vonoprazan is efficacious for treatment of heartburn in non-erosive reflux disease: a randomized trial. Clin Gastroenterol Hepatol. 2024;22(11):2211–2220.e10. doi:10.1016/j.cgh.2024.05.004. DOI: https://doi.org/10.1016/j.cgh.2024.05.004
Uemura N, Kinoshita Y, Haruma K, Yao T, Kushima R, Ishiguro K, et al. Vonoprazan as a long-term maintenance treatment for erosive esophagitis: VISION, a 5-year, randomized, open-label study. Clin Gastroenterol Hepatol. 2025;23(5):748–757.e5. doi:10.1016/j.cgh.2024.08.004. DOI: https://doi.org/10.1016/j.cgh.2024.08.004
Qiao X, et al. Potassium-competitive acid blockers and advances in the management of acid-related diseases. Front Pharmacol. 2025. doi:10.3389/fphar.2024.1477633. DOI: https://doi.org/10.3389/fphys.2025.1655102
Scarpignato C, Hunt RH. Potassium-competitive acid blockers: current clinical use and future developments. Curr Gastroenterol Rep. 2024;26:273–293. doi:10.1007/s11894-024-00939-3 DOI: https://doi.org/10.1007/s11894-024-00939-3
Leowattana W, Leowattana T. Potassium-competitive acid blockers and gastroesophageal reflux disease. World J Gastroenterol. 2022;28(28):3608–3619. doi:10.3748/wjg.v28.i28.3608. DOI: https://doi.org/10.3748/wjg.v28.i28.3608
Yadlapati R, Gyawali CP, Pandolfino JE; CGIT GERD Consensus Conference Participants. AGA Clinical Practice Update on the personalized approach to the evaluation and management of gastroesophageal reflux disease: expert review. Clin Gastroenterol Hepatol. 2022;20(5):984–994.e1. doi:10.1016/j.cgh.2022.01.025. DOI: https://doi.org/10.1016/j.cgh.2022.01.025
Scarpignato C, de Bortoli N, Iovino P, Nacci A, Sarnelli G, Savarino EV. Hyaluronic acid and chondroitin sulfate-based medical devices: formulations, esophageal mucosal protection, and their place in the management of GERD. Ther Adv Gastroenterol. 2025;18:17562848251337822. doi:10.1177/17562848251337822. DOI: https://doi.org/10.1177/17562848251337822
Savarino V, Pace F, Scarpignato C; Esoxx Study Group. Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of non-erosive reflux disease—efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation. Aliment Pharmacol Ther. 2017;45(5):631–642. doi:10.1111/apt.13914. DOI: https://doi.org/10.1111/apt.13914
Leiman DA, Riff BP, Morgan S, Metz DC, Falk GW, French B, Umscheid CA, Lewis JD. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30(5):1–9. doi:10.1093/dote/dow020. DOI: https://doi.org/10.1093/dote/dow020
Reimer C, Lødrup AB, Smith G, Wilkinson J, Bytzer P. Randomised clinical trial: alginate added to a proton pump inhibitor in patients with persistent reflux symptoms despite standard-dose proton pump inhibitor. Aliment Pharmacol Ther. 2016;43(8):899–909. doi:10.1111/apt.13567. DOI: https://doi.org/10.1111/apt.13567
Savarino E, Bredenoord AJ, Fox M, Pandolfino JE, Roman S, Gyawali CP; International Working Group for Disorders of Gastrointestinal Motility and Function. Advances in the physiological assessment and diagnosis of GERD. Nat Rev Gastroenterol Hepatol. 2018;15(5):323. doi:10.1038/nrgastro.2018.36. DOI: https://doi.org/10.1038/nrgastro.2018.32
Gyawali CP, Kahrilas PJ, Savarino E, Zerbib F, Mion F, Smout AJPM, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;67(7):1351–1362. doi:10.1136/gutjnl-2017-314722. DOI: https://doi.org/10.1136/gutjnl-2017-314722
Scarpignato C, Gatta L, Zullo A, Blandizzi C; SIF-AIGO-FIMMG Group. Effective and safe proton pump inhibitor therapy in acid-related diseases—a position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016;14:179. doi:10.1186/s12916-016-0718-z. DOI: https://doi.org/10.1186/s12916-016-0718-z
Woodland P, Sifrim D. Esophageal mucosal integrity in nonerosive reflux disease. J Clin Gastroenterol. 2014;48(1):6–12. doi:10.1097/MCG.0000000000000019. DOI: https://doi.org/10.1097/MCG.0b013e318299f181
Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F. Functional esophageal disorders. Gastroenterology. 2016;150(6):1368–1379. doi:10.1053/j.gastro.2016.02.012. DOI: https://doi.org/10.1053/j.gastro.2016.02.012
Roman S, Keefer L, Imam H, Korrapati P, Mogni B, Eident K, et al. Majority of symptoms in esophageal reflux PPI non-responders are not related to reflux. Neurogastroenterol Motil. 2015;27(11):1667–1674. doi:10.1111/nmo.12666. DOI: https://doi.org/10.1111/nmo.12666
Bredenoord AJ, Weusten BLAM, Curvers WL, Timmer R, Smout AJPM. Determinants of perception of heartburn and regurgitation. Gut. 2006;55(3):313–318. doi:10.1136/gut.2005.074690. DOI: https://doi.org/10.1136/gut.2005.074690
Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on de-prescribing of proton pump inhibitors: expert review. Gastroenterology. 2022;162(4):1334–1342. doi:10.1053/j.gastro.2021.12.247. DOI: https://doi.org/10.1053/j.gastro.2021.12.247
Uemura N, Kinoshita Y, Haruma K, Yao T, Kushima R, Kanoo T. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. Clin Exp Gastroenterol. 2018;11:51–56. doi:10.2147/CEG.S144149. DOI: https://doi.org/10.2147/CEG.S144149
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Azerbaijan Gastroenterology and Invasive Endoscopy Society
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
